MAP2K7 and hepatocellular carcinoma: Fortunately, combined with our previous findings that the activation of both MEK/ERK and p38 signaling pathways restrained the efficacy of ARV-771, we spontaneously explored the effect of sorafenib in combination with ARV-771 in HCC cells.